Introduction
The investigation of molecular mechanisms underlying the cell malignant transformation and tumor growth is the task of the great actuality so far. The discovery of the protein hydrolysis system in the 1980s involving proteasomes and touching all cellular processes provided a new impulse to the studies in this area. Proteasomes, multisubunit multiproteinase complexes, are present in mammalian cells in multiple forms with different structures and physiological functions [1] [2] [3] [4] . Depending on the nature of the protease subunits, proteasomes can be divided into two groups, the constitutive and immune proteasomes. The constitutive proteasomes contain two of each of the X(β5), Y(β1) and Z(β2) subunits, possessing the chymotrypsin-like (ChTL), caspaselike (CL), and trypsin-like (TL) activities, respectively. The immune proteasomes contain the LMP7 (β5i), LMP2 (β1i), and LMP10 (MECL1, β2i) immune subunits instead of the above-mentioned protease subunits of the constitutive proteasomes. The substrate binding pockets of the immune proteasomes differ from that of the constitutive ones and may be the reason of the cleavage preference for certain peptide bonds [5] . The immune proteasomes possess the altered cleavage site preference with a strong predominance to cleave behind basic or hydrophobic residues that represent the correct C terminus of a major histocompatibility complex (MHC) class I epitope. Thus, the immune proteasomes successfully produce antigenic epitopes of 8-10 amino acid residues and/or their more long precursors from foreign (mutant, tumor or viral) proteins. Epitope precursors are shortened by amino peptidases in the cytoplasm or endoplasmic reticulum where they are transferred by special proteins-transporters [6] [7] [8] .
In the endoplasmic reticulum antigenic epitopes are bound with MHC class I molecules and transported in trans-membrane vesicles onto the cell surface for presentation to T-CD8 lymphocytes.
Besides, the immune proteasomes control the differentiation and proliferation of some cell populations, perhaps, by the production of biologically active peptides or regulation of the transcription factor activities [9, 10] . The immune proteasomes are also an essential part of the signalling pathway responsible for quenching the oxidative stress [11] .
Both constitutive and immune proteasomes form pools of the 26S-and 20S proteasomes [3] . Overall, the 26S proteasome pool may be indicated as 19S-20S + 19S-20S-19S + 19S-20S-Reg, where 20S is the core proteolytic particle; 19S is the activator responsible for binding to ubiquitinated target proteins, unfolding and directing them into the proteolytic chamber; Reg is one of the different regulator proteins (PA28, PA200, PI31). Thus, the 26S proteasomes regulate cellular processes by degrading the proteins or forming the peptides involved in those processes. They also trigger the reactions associated with the T cell immune response. The 26S proteasome functions are generally dependent on ubiquitin and ATP utilized by six ATPases of the AAA family (ATPase associated with various cellular activities) included in 19S structure [12] . The 20S proteasomes, on the contrary, degrade proteins and short peptides independently of ATP and ubiquitin. The list of proteins identified as substrates of 20S proteasomes extends every year; it includes, for example, proteins with a damaged tertiary structure [13] and some virus proteins [14, 15] .
The determination of changes occurring in the proteasome pool during the tumor development is important for realizing some mechanisms of this process, as well as for finding the new targets for the anticancer therapy among the multiple proteasome forms. The scarce published data on this matter concern the comparison of the content of separate proteasome forms in human malignant and control cells [16] [17] [18] [19] [20] [21] [22] . The present research is dedicated to the study of proteasome mechanisms underlying the development of human papillary thyroid carcinoma. The ChTL and CL activities and the expression of the total proteasome pool, as well as the expression of the 19S particle and constitutive and immune protease subunits were investigated in patients with different stages of papillary thyroid carcinoma and compared to control tissues.
Experimental Procedures

Samples of thyroid gland tissues
Samples of tumors and tissues adjacent and distant (3-4 cm) from the tumor were obtained from thyroid gland parts surgically removed from patients with verified papillary thyroid carcinoma at the stage T 2 N 0 M 0 (9 females of 39-56 years old) and at the stage T 3 N 0 M 0 (7 females of 40-52 years old) at the Central Hospital of Russian Academy of Sciences and Department of General Surgery of Russian State Medical University after the approval of the local ethics committees and informed consent according to the Declaration of Helsinki. Histological analysis of tumors was performed by standard Pappenheim method.
Antibodies and reagents
Combined mouse monoclonal antibodies (mAbs) to the subunits α1,2,3,5,6,7, mouse mAbs to the subunit Rpt6, rabbit polyclonal antibodies (pAbs) to the constitutive subunits X(β5) and Y(β1) and immune subunits LMP7 (β5i) and LMP2 (β1i) and mouse mAbs to the subunit LMP2 (β1i) of proteasomes were purchased from Biomol (UK). Mouse mAbs to β actin and to human proteins CD3, CD14 and CD19 were purchased from Santa Cruz (Germany). Mouse mAbs to cytokeratin 18 and cytokeratin 19 were purchased from Millipore (USA) and Acris (Germany) respectively. Rabbit mAbs to human MHC class I molecules were purchased from Epitomics (USA). Peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG antibodies, and ECL reagents were purchased from Amersham Biosciences (UK). Hoechst 33342, Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor 546 goat anti-mouse IgG, Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 488 goat anti-mouse IgG were purchased from Invitrogen (USA). Proteasome substrates, N-succinyl-leu-leu-val-tyr7-amido-4-methyl coumarin (Suc-LLVY-AMC) (Sigma, USA) and Z-LeuLeu-Glu-AMC (Z-LLE-AMC) (Tebu-Bio, Belgium), and inhibitors, Z-leucyl-leucyl-leucinal (MG132) (Sigma, USA) and adamantaneacetyl-(6-aminohexanoyl) 3 -(leucyl) 3 -vinylmethyl-sulfone (AdaAhx(3)L(3)VS) (Enzo, UK) were used.
Preparation of cleared homogenates
All procedures were performed at 4°C. Samples of tumors and adjacent and distant tissues were homogenized in a Braun Melsungen (Germany) homogenizer (glassglass) in buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 10% glycerol, 10 mM Na 2 S 2 O 5 , leupeptin (0.5 μg/ml), pepstatin (1 μg/ml), aprotinin (1 μg/ml) in the ratio 1:3 (w:v). Homogenates were centrifuged at 10,000 g for 30 min. Supernatants (cleared homogenates) were used for further investigation. Protein concentration in cleared homogenates was determined by Lowry method [23] .
Determination of proteasome activities
The ChTL-and CL proteasome activities were determined by hydrolysis of fluorogenic peptides Suc-LLVY-AMC and Z-LLE-AMC, accordingly. The reaction mixture contained 20 mM Tris-HCl (pH 7.5), 1 mM DTT, 5 mM MgCl 2 , 1 mM ATP, and 30 μM Suc-LLVY-AMC or Z-LLE-AMC. The reaction was performed at 37°C for 20 min after the introduction of 0.5-2 μl of the proteasome fraction into the reaction mixture (to the final volume of 100 μl) and stopped by the addition of 1% SDS. The resulting product was detected by a fluorometer with the excitation wavelength of 380 nm and the emission wavelength of 440 nm. To calculate the contribution of the extrinsic proteolytic activities, MG132 as the inhibitor of the ChTL proteasome activity and AdaAhx(3)L(3)VS as the inhibitor of the CL proteasome activity were used [24, 25] . The effects of these inhibitors were preliminarily investigated with the use of proteasomes purified from the rat liver and liberated from admixed proteases as described earlier [26] . 5 μM MG132 completely inhibited the ChTL activity of purified proteasomes. However, AdaAhx(3)L(3)VS did not inhibit the proteasome CL activity completely displaying the maximal effect (90%) at the concentration 20 μM. So, the final calculation of the ChTL proteasome activity was performed as the difference between the total and residual activities in the presence of 5 μM MG132. The final calculation of the CL proteasome activity was performed as the difference between the total and residual activities in the presence of 20 μM AdaAhx(3)L(3)VS. The result was normalized by the division by 0.9 to obtain 100% value. In the present investigation, the residual ChTL-and CL activities were 2-7% and 11-16% accordingly.
Western blotting
After SDS-PAGE in 13% gel (5 μl/120-185 μg of cleared homogenate per lane), the polypeptides were semi-dry transferred from the gel onto a nitrocellulose membrane. The membrane was incubated for 2 h at 20°C in TNT buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween-20), then for 1 h in TNT buffer containing 5% defatted milk and primary mAbs or pAbs, washed several times in the TNT buffer and incubated for 1 h in the TNT buffer containing 5% defatted milk and appropriate peroxidase-conjugated antibodies to mouse or rabbit IgG diluted 1 : 5000. After washing in TNT buffer, the membrane was treated routinely using the ECL system.
The image analysis was performed using "ImageJ" software. The relative quantities (the optical densities) of the immunoreactive bands on X-ray film were measured as the "gray level" (GL) which is related to the optical density (OD) of the specimen as follows [27] :
The dependence of the optical density on the amount of the protein subjected to Western blotting was evaluated preliminarily. For the further procedure, the diapason of the protein amount was chosen, in which this dependence was linear.
Immunohistochemistry
Samples of tumors and adjacent and distant tissues were fixed in 4% paraformaldehyde and frozen. Cryostat sections (10 μm) were subsequently incubated at room temperature with: 1) PBS containing 1% of BSA and 0.1% Triton X-100 for 1 h; 2) PBS containing 1% of BSA, 0.1% Triton X-100 and primary rabbit pAbs to LMP7 or mouse mAbs to LMP2 or Rpt6 or α1,2,3,5,6,7 (1 : 2500) or mixture of primary rabbit pAbs to LMP7 and mouse mAbs to LMP2 (1 : 2500) or CD3 or CD19 or CD14 Images were recorded and processed with the Leica LCS software. Control experiments were performed by omitting either the primary or secondary antibodies.
In some experiments, all slices of tumors and distant tissues were treated with the same antibodies. The images obtained (10 3 cells of distant tissues and 3 × 10 3 tumor cells) were analyzed by "ImageJ" software and the intensity of fluorescent labeling per cell was evaluated [27] .
Statistical analysis
The data are presented as the mean ± the confidential interval (d):
, where t is the Student coefficient for P<0.05, s is the standard deviation, n is the number of experiments.
Results
In Figure 1 , an image of a papillary thyroid carcinoma cells is presented. Such image was typical for studied tumors at the stages T 2 N 0 M 0 and T 3 N 0 M 0 . The ChTL-and CL proteasome activities were evaluated by hydrolysis of commercial fluorogenic peptides, the results being normalized to β actin amount. It was shown that both the ChTL activity and CL activity were identical in the thyroid tissues distant from tumors of the different development stages (Table 1) . They slightly increased in the tumor at the stage T 2 N 0 M 0 . At the same time, both activities increased significantly in the tumor and adjacent tissue at the stage T 3 N 0 M 0 . In the tumor, the ChTL activity increased by 4 times and the CL activity by 5 times compared to those in the distant tissue. In the adjacent tissue, the ChTL activity was 80% higher and CL activity was 140% higher compared to those in the distant tissue. Changes in the expression of the subunits X(β5) and LMP7 (β5i) displaying the ChTL activity and that of the subunits Y(β1) and LMP2 (β1i) displaying the CL activity in the papillary thyroid carcinoma development were investigated by Western blotting (Figure 2 , Table 1 ). The data were normalized to β actin level. It was detected that the expression of each of the immune and constitutive protease subunits was conserved in the tissues distant from the tumors of the different development stages, similar with the ChTL-and CL activities. The expression of the immune subunits and constitutive X(β5) subunit was enhanced in the papillary thyroid carcinoma at both development stages in comparison with that in the distant tissues. The LMP7 (β5i) amount increased by 30% and 160%, the LMP2 (β1i) amount increased by 100% and 300% and the X(β5) amount increased by 26% and 70% in the carcinoma at the stages T 2 N 0 M 0 and T 3 N 0 M 0 respectively. The expression of these subunits did not differ evidently in the tissues adjacent to the tumors at both stages. However, the expression of the constitutive subunit Y(β1) was 30% lower in the carcinoma at both development stages and in the tissue adjacent to the tumor at the T 3 N 0 M 0 stage in comparison with that in the distant tissues.
Changes in the ChTL
Changes in the expression
LMP7(β5i) 100±9 (*100±12) 88±7 131±13 (*176±22) 105±9 109±10 262±35 (*215±20) X(β5) 100±13 106±11 126±16 92±10 92±11 164±30 LMP2(β1i) 100±10 (*100±14) 97±7 214±25 (*280±19) 115±14 118±15 417±41 (*376±28) Y(β1) 100±8 104±11 69±8 105±7 70±9 71±8
Changes in the expression of the 19S particle and total proteasome pool in the papillary thyroid carcinoma at the stages T 2 N 0 M 0 and T 3 N 0 M 0
The expression of the 19S particle was examined by Western blotting with the use of the Abs to the Rpt6 subunit included in its structure. The expression of the total proteasome pool was investigated in a similar way, with the use of the combined Abs to the subunits α1,2,3,5,6,7, included in the structure of all proteasome forms. The data are represented in Figure 2 and Table 1 . The expression of the Rpt6 subunit did not differ reliably in the tissues distant from the tumors at both development stages as well as in the tissue adjacent to the tumor at the T 2 N 0 M 0 stage. Its level was 80% and 240% higher in the carcinoma at the T 2 N 0 M 0 and T 3 N 0 M 0 stages respectively, and it was 45% higher in the tissue adjacent to the carcinoma at the T 3 N 0 M 0 stage than in the distant tissues. Discovered changes in the levels of the proteasome subunits were accompanied by the increase of the total proteasome pool. The distribution of the LMP7 (β5i) subunit in the cells of the papillary thyroid carcinoma at the stages T 2 N 0 M 0 and T 3 N 0 M 0 and in the cells of the adjacent and distant tissues is represented in Figure 3 . To distinguish the LMP7 (β5i) distribution in stromal and cancer cells, co-staining by mouse mAbs to cytokeratins and rabbit pAbs to the LMP7 (β5i) subunit was performed ( Figure 4 ). This experiment showed that: thyroid gland cells in the distant tissue sample expressed cytokeratins; the cancer tissue sample contained very few stromal cells expressing cytokeratins; the LMP7 (β5i) expression was higher in cancer cells in comparison with that in normal thyroid gland cells.
At the same time, the great heterogeneity in the LMP7 (β5i) distribution in the cells of the tumor at the T 3 N 0 M 0 stage was detected (Figure 3) . The similar heterogeneity in the cellular distribution was established also for the LMP2 (β1i) subunit ( Figure 5B) . The difference in the cellular distribution of the Rpt6 or α1,2,3,5,6,7 subunits was expressed to the less extent ( Figure 5A and C). The results obtained have raised questions concerning the colocalization of the LMP7(β5i) and LMP2(β1i) subunits and identification of cells enriched by these subunits.
It was revealed by the method of double immunofluorescent staining that the LMP7 (β5i) and LMP2 (β1i) subunits were generally colocalized ( Figure 6A−C) . Also, it was shown that cells enriched by the immune subunits were the infiltrated cells of the immune system: T lymphocytes ( Figures 6D−F and 7E−H) , B lymphocytes ( Figure 6G−I) , macrophages/monocytes ( Figures 6J−L and 7A−D) .
Thus, the immune subunits of these cells contributed to the total level of the immune subunits in the tumor detected by Western blotting. In addition to the data obtained by Western blotting we evaluated the amount of some proteasome subunits per control or tumor cell (Table 1) . It was detected by both methods that the expression of the Rpt6 and LMP2 (β1i) subunits increased greater than the expression of other proteasome subunits in the papillary thyroid carcinoma development. 
Discussion
Technical remarks
(1) It is necessary to take into consideration that high proteasome subunit mRNA levels do not always correlate with high protein levels, suggesting a specific translation mechanism which controls proteasome subunit synthesis [28] . So, our attention was paid exactly to the protein expression of the proteasome subunits.
(2) The specificity of rabbit pAbs to the LMP7 subunit was verified by the immunohistochemistry performed on the slices of the rat brain which contains a very small amount of the immune proteasomes in comparison with other organs [29] .
(3) Molecular masses of the α1,2,3,5,6,7 subunits are in the range of 27−33 kDa, some of them being identical [4] . It is the reason of revealing only two bands by Western blotting (Figure 2 ).
Changes in the proteasome pool in the development of human papillary thyroid carcinoma
For the first time, the study of the proteasome mechanisms of human malignant tumor development was performed. The changes in the proteasome pool in the papillary thyroid carcinoma at the T 2 N 0 M 0 and T 3 N 0 M 0 stages in comparison with the distant control tissues were discovered. These changes had both similarities and differences. At both stages, the total proteasome pool as well as the expression of the subunits Rpt6, X(β5) and immune subunits LMP7 (β5i) and LMP2 ( The third immune subunit, MECL1 (β2i), is known to be integrated into assembling proteasomes jointly with the subunit LMP2 (β1i) but independently from the subunit LMP7 (β5i). Although the integration of the LMP7 (β5i) subunit into the proteasome is facilitated by the presence of the LMP2 (β1i) and MECL1 (β2i) subunits, it can be realized in their absence as well [30, 31] . Thus, three types of the immune proteasomes may be formed: the type containing all three immune catalytic subunits, the type containing the LMP2 (β1i) and MECL1 (β2i), and the type possessing only the LMP7 (β5i). The different level of the enhancement of the LMP7 (β5i) and LMP2 (β1i) expression in the carcinoma at both stages (Table 1 ) indicates the presence of the different types of the immune proteasomes in it.
Note, the changes in the proteasome pool involve also the tissue adjacent to the carcinoma at the T 3 N 0 M 0 stage, unlike to that at the T 2 N 0 M 0 stage (Table 1) . This characteristic may serve as an indicator of tumor progression.
Overall, the enhanced expression of the 19S particle and different types of the immune proteasomes is likely to underlie the development of the papillary thyroid carcinoma. The reason of the overexpression of the 19S particle characterizing the 26S proteasome pool in carcinoma is clear. The high level of the protein metabolism is typical for malignant tumors [32, 33] which, in turn, requires the high level of the proteolytic enzymes including the 26S proteasomes. However, the cause of the immune proteasome overexpression is more complicated. On the one hand, the LMP2 (β1i) subunit is important for the development of the oncocytic phenotype and primary hypothyroidism in mice [22] . On the other hand, the immune subunits play the antitumor role producing the antigen epitopes for MHC class I molecules to reveal the tumor cells to the cytotoxic T lymphocytes. Indeed, oncoproteins typically expressed in human papillary thyroid carcinoma trigger a proinflammatory programme [34] . These data coincide with our results on detection of the immune system cells in the papillary thyroid carcinoma at the T 3 N 0 M 0 stage. This raises the question, why did the immune system not destroy the tumor cells? In spite of the enhanced expression of the immune proteasomes, some other components necessary for the immune reaction development may be absent in the tumor cells. To check this suggestion, we investigated the expression of the MHC class I molecules in the tumors at the T 2 N 0 M 0 and T 3 N 0 M 0 stages. In fact, the MHC class I molecules were poorly detected in the tumor only at the T 3 N 0 M 0 stage. Most likely, the detected molecules belonged to the infiltrating cells of the immune system, but not to the tumor cells. The investigation of this matter will be our future task.
Thus, the deficit of the MHC class I molecules in the papillary thyroid carcinoma may be the cause of the inability of the immune system to induce apoptosis in the carcinoma cells. Moreover, some experimental data indicate that the infiltrated cells of the immune system exert a protumorogenic function [34] . Based on these data, Guarino and coauthors proposed that inflammatory molecules were promising targets for thyroid cancer therapy. Besides, the LMP2 (β1i) subunit was also indicated as a potential therapeutic target in oncocyte pathogenesis in the thyroid gland [22] . In the present study, we discovered that the level of both the LMP2 (β1i) subunit and the 19S particle was enhanced to approximately equal degrees in human papillary thyroid carcinoma development. Taking into consideration the antitumor function of the immune proteasomes, we suggest the 19S particle as a target for the development of a novel therapeutic strategy.
Note that among antitumor drugs Bortezomib (Velcade ® , PS-341) is the first drug related to the proteasome functions [35] . Bortezomib competitively inhibits the ChTL activity of all proteasome forms and induces apoptosis preferentially in neoplastic cells. At the same time, bortezomib exhibits side effects: fatigue and weakness, gastrointestinal disturbances, thrombocytopenia, acute pancreatitis, encephalopathy syndrome [35] [36] [37] . Besides, under the pressure of the continuous proteasome inhibition, cells switch on adaptive feedback mechanisms to eliminate the lethal attack of proteasome inhibitors [38, 39] . Such mechanisms include the increased proteasome expression and enhanced proteolytic activity. This explains the temporary therapeutic effect of bortezomib. In this connection, a novel drug damaging the functions of the 19S particle promises to be more effective and safe in antitumor therapy.
